Print
In the early 1980s, as AIDS was beginning its deadly tear, a Catholic priest told a radio audience in Boston that he sympathized with people who didn’t want to be around anyone who had the disease.
Dr. Robert “Chip” Schooley about popped a vein.
The young Harvard physician and infectious-disease expert got in touch with the station and relayed a blunt message to the priest: “If you ever make a comment like that again, I will reveal that the church is keeping priests who have AIDS out of sight at a monastery in Newton [Mass.].”
“He was stoking fears people had about those with HIV. It was wrong,” said Schooley, who has spent the past 16 years on the UC San Diego faculty.
Synairgen plc: Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
( Synairgen or the Company )
Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
Southampton, UK - 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled interferon beta formulation (SNG001) sub-study of the ACTIV-2 Phase II/III trial, evaluating patients with mild to moderate COVID-19 symptoms not yet requiring hospitalisation.
Richard Marsden, CEO of Synairgen, said:
Four potential COVID-19 therapeutics enter Phase 2/3 testing
Enrollment has begun to test additional investigational drugs in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. ACTIV is a public-private partnership program to create a coordinated research strategy that prioritizes and speeds development of promising COVID-19 treatments and vaccines. The new agents entering the randomized, placebo-controlled study are part of ACTIV-2, an adaptive trial designed to test investigational agents in non-hospitalized adult volunteers experiencing mild to moderate COVID-19 symptoms. ACTIV-2 is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, and is led by the NIAID-funded AIDS Clinical Trials Group (ACTG).
Print
In the early 1980s, as AIDS was beginning its deadly tear, a Catholic priest told a radio audience in Boston that he sympathized with people who didn’t want to be around anyone who had the disease.
Robert “Chip” Schooley about popped a vein.
The young Harvard physician and infectious disease expert got in touch with the station and relayed a blunt message to the priest: If you ever make a comment like that again, I will reveal that the church is keeping priests who have AIDS out of sight at a monastery in Newton.
“He was stoking fears people had about those with HIV. It was wrong,” said Schooley, who has spent the past 16 years on the UC San Diego faculty.
Enrollment has begun to test additional investigational drugs in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. ACTIV.